Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wanbury Limited ( (IN:WANBURY) ) has provided an update.
Wanbury Limited announced several key decisions following its Board of Directors meeting on August 4, 2025. The company approved its unaudited financial results for the first quarter ending June 30, 2025, and granted 91,500 stock options to employees under its Employee Stock Option Plan 2016. Additionally, the reappointment of Mr. Chandran Krishnamurthy as a Whole-time Director for a five-year term was approved, pending shareholder approval. Furthermore, Wanbury Limited initiated the closure of three foreign subsidiaries, which had not commenced operations, ensuring no impact on the company’s revenue or business.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical products. The company is known for its range of formulations and active pharmaceutical ingredients (APIs), catering to various therapeutic segments.
Average Trading Volume: 11,284
Technical Sentiment Signal: Buy
Current Market Cap: 8.87B INR
For an in-depth examination of WANBURY stock, go to TipRanks’ Overview page.